Betablockers are indicated for secondary prevention of coronary artery disease (CAD). However, in patients with comorbidity of chronic obstructive pulmonary disease (COPD) an underuse of betablocker has been reported.
Materials and Methods
Prescription and demographic data and information on hospital discharge diagnoses from 13 Austrian health insurance funds for the years 20062007 were analyzed. The primary end point was allcause mortality of patients with CAD with or without COPD and its association with use of betablockers.
In 2006 and 2007, 65717 patients (37% female, 63% male) were discharged with a diagnosis of CAD. Among these patients, 46% had a codiagnosis of COPD, 24% had diabetes, and 75% received betablockers. Use of betablockers was comparable in CAD patients with COPD and without COPD with 77% and 74%, respectively.
Thousand eight hundred seventytwo (8.1%) and 1473 (5.6%) patients with and without COPD, who used betablockers died within months in 2006 and 2007. Thousand five hundred fiftythree (22.0%) and 1862 (22.2%) of patients with and without COPD and without betablockers died during the corresponding time period.
Use of betablockers was similar in patients with CAD with or without codiagnosis of COPD. However, mortality of betablocker users was markedly lower than that of nonusers in patients with CAD with or without COPD.